Author

A. D. Bins

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Assay:flow cytometry· 1 Organism:human· 1 Organism:mouse· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

A. Jongejan· 1 shared A. Redeker· 1 shared C. J. A. Punt· 1 shared E. Beyranvand Nejad· 1 shared E. J. Redeker· 1 shared E. T. I. van der Gracht· 1 shared F. J. van Haften· 1 shared F. Ossendorp· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Jongejan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

OX40 agonism enhances efficacy of PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum

G. Beyrend, T. C. van der Sluis, E. T. I. van der Gracht, T. Abdelaal, S. P. Jochems, R. A. Belderbos, T. H. Wesselink, S. van Duikeren, F. J. van Haften, A. Redeker, E. Beyranvand Nejad, M. Camps, K. L. M. C. Franken, M. M. Linssen, P. Hohenstein, , R. Arens

This study shows that OX40 agonism improves PD-L1 checkpoint blockade by altering T cell differentiation, leading to enhanced anti-tumor immunity through dynamic expression of NK and chemokine receptors.

bioRxiv · Dec 24, 2021 · PreprintImmunology

Framing the potential of public frameshift peptides as immunotherapy targets in colon cancer

I. T. Spaanderman, F. S. Peters, A. Jongejan, E. J. Redeker, C. J. A. Punt, A. D. Bins

The paper identifies 20 frameshift peptides in MSI colon cancer patients that could serve as immunotherapy targets, covering most patients and Lynch syndrome cases.

bioRxiv · Mar 26, 2020Cancer Biology